tiprankstipranks
Atai Life Sciences price target lowered to $10 from $20 at Citi
The Fly

Atai Life Sciences price target lowered to $10 from $20 at Citi

Citi analyst Neena Bitritto-Garg lowered the firm’s price target on Atai Life Sciences to $10 from $20 and keeps a Buy rating on the shares. The analyst removed PCN-101 from her model following data from the Phase 2a study. Given the lack of meaningful upside catalysts in 2023, Atai shares could remain relatively range-bound near-term, Bitritto-Garg tells investors in a research note.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on ATAI:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles